trending Market Intelligence /marketintelligence/en/news-insights/trending/qcKMTZlpjrj9zX80DUYJ8w2 content esgSubNav
In This List

Aurobindo recalls 1 lot of depressive disorder tablets due to label error

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Aurobindo recalls 1 lot of depressive disorder tablets due to label error

Aurobindo Pharma USA Inc. recalled one lot of its mirtazapine tablets due to a label error on the medicine's declared strength.

The voluntary recall was made as 7.5-milligram mirtazapine bottles may contain 15-milligram tablets, the U.S. Food and Drug Administration said in a news release.

Mirtazapine is used for treating major depressive disorder. Taking a higher dose of the drug than expected may increase the risk of sedation, agitation, increased reflexes, tremor, sweating, dilated pupils, gastrointestinal distress, nausea, constipation and other effects.

Aurobindo Pharma USA is also notifying its distributors and is arranging for the return of all of the recalled product.

Aurobindo Pharma USA is the U.S. unit of Indian pharmaceutical company Aurobindo Pharma Ltd.